NO314458B1 - Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon - Google Patents

Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon Download PDF

Info

Publication number: NO314458B1
Authority: NO; Norway
Prior art keywords: cells; antigen; gene; construct; mhc
Prior art date: 1989-07-25

Application number

NO19911164A

Other languages

English (en)

Norwegian (no)

Other versions

NO911164L (no

NO911164D0 (no

Inventor

Raju S Kucherlapati

Beverly H Koller

Oliver Smithies

Original Assignee

Cell Genesys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-25

Filing date

1991-03-22

Publication date

2003-03-24

1991-03-22 Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc

1991-03-22 Publication of NO911164L publication Critical patent/NO911164L/no

1991-03-22 Publication of NO911164D0 publication Critical patent/NO911164D0/no

2003-03-24 Publication of NO314458B1 publication Critical patent/NO314458B1/no

Links

238000000034 method Methods 0.000 title claims description 19
210000004962 mammalian cell Anatomy 0.000 title claims description 17
238000010276 construction Methods 0.000 title claims description 12
210000004027 cell Anatomy 0.000 claims abstract description 97
108090000623 proteins and genes Proteins 0.000 claims abstract description 49
102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract description 5
108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 5
239000000427 antigen Substances 0.000 claims description 51
108091007433 antigens Proteins 0.000 claims description 51
102000036639 antigens Human genes 0.000 claims description 51
230000003902 lesion Effects 0.000 claims description 19
230000009466 transformation Effects 0.000 claims description 13
230000014509 gene expression Effects 0.000 claims description 12
230000002779 inactivation Effects 0.000 claims description 12
230000010354 integration Effects 0.000 claims description 12
239000003550 marker Substances 0.000 claims description 12
210000002510 keratinocyte Anatomy 0.000 claims description 10
210000001519 tissue Anatomy 0.000 claims description 4
238000013507 mapping Methods 0.000 claims description 3
230000001131 transforming effect Effects 0.000 claims description 3
230000006801 homologous recombination Effects 0.000 abstract description 11
238000002744 homologous recombination Methods 0.000 abstract description 11
108010081355 beta 2-Microglobulin Proteins 0.000 abstract description 7
210000001671 embryonic stem cell Anatomy 0.000 abstract 1
230000009261 transgenic effect Effects 0.000 abstract 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 33
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 33
108020004414 DNA Proteins 0.000 description 25
238000012217 deletion Methods 0.000 description 13
230000037430 deletion Effects 0.000 description 13
239000013612 plasmid Substances 0.000 description 11
239000012634 fragment Substances 0.000 description 10
239000013598 vector Substances 0.000 description 9
210000000987 immune system Anatomy 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
108020004440 Thymidine kinase Proteins 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000002103 transcriptional effect Effects 0.000 description 5
108091026890 Coding region Proteins 0.000 description 4
229930193140 Neomycin Natural products 0.000 description 4
229960004150 aciclovir Drugs 0.000 description 4
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
230000000735 allogeneic effect Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
229960002963 ganciclovir Drugs 0.000 description 4
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
229960004927 neomycin Drugs 0.000 description 4
239000000523 sample Substances 0.000 description 4
241000894007 species Species 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
230000005026 transcription initiation Effects 0.000 description 4
108010058597 HLA-DR Antigens Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
102000015736 beta 2-Microglobulin Human genes 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
210000005175 epidermal keratinocyte Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
210000004153 islets of langerhan Anatomy 0.000 description 3
239000010410 layer Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000003098 myoblast Anatomy 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000002207 retinal effect Effects 0.000 description 3
108700028369 Alleles Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000007123 defense Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
208000029257 vision disease Diseases 0.000 description 2
-1 (3-actin Proteins 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101710094503 Metallothionein-1 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000013521 Visual disease Diseases 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000008004 immune attack Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000003994 retinal ganglion cell Anatomy 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Environmental Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Veterinary Medicine (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
Lubricants (AREA)
Special Wing (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

NO19911164A 1989-07-25 1991-03-22 Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon NO314458B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38565189A	1989-07-25	1989-07-25
US43187289A	1989-11-06	1989-11-06
PCT/US1990/004178 WO1991001140A1 (en)	1989-07-25	1990-07-25	Homologous recombination for universal donor cells and chimeric mammalian hosts

Publications (3)

Publication Number	Publication Date
NO911164L NO911164L (no)	1991-03-22
NO911164D0 NO911164D0 (no)	1991-03-22
NO314458B1 true NO314458B1 (no)	2003-03-24

Family

ID=27011096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19911164A NO314458B1 (no)	1989-07-25	1991-03-22	Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon

Country Status (9)

Country	Link
US (1)	US5416260A (ja)
EP (2)	EP0437576B1 (ja)
JP (1)	JPH04501510A (ja)
KR (1)	KR100226158B1 (ja)
AT (1)	ATE423195T1 (ja)
AU (1)	AU633958B2 (ja)
DE (2)	DE69034263D1 (ja)
NO (1)	NO314458B1 (ja)
WO (1)	WO1991001140A1 (ja)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5705732A (en) *	1989-06-12	1998-01-06	Oklahoma Medical Research Foundation	Universal donor cells
US5538722A (en) *	1989-06-13	1996-07-23	Stanford University	Isolation, growth, differentiation and genetic engineering of human muscle cells
US5574205A (en) *	1989-07-25	1996-11-12	Cell Genesys	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5464764A (en) *	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
US6689610B1 (en) *	1989-08-22	2004-02-10	University Of Utah Research Foundation	Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
US6673986B1 (en) *	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5877397A (en) *	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) *	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) *	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US7041871B1 (en) *	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5489742A (en) *	1990-10-23	1996-02-06	Board Of Regents, The University Of Texas System	Transgenic rats and animal models of inflammatory disease
WO1992009688A1 (en) *	1990-11-21	1992-06-11	Massachusetts Institute Of Technology	MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
ATE263837T1 (de) *	1991-05-31	2004-04-15	Genentech Inc	Expressionsteigerung durch gentargeting in endogene retrovirus-ähnliche sequenzen
EP1041142A3 (en) *	1991-07-15	2007-10-24	Oklahoma Medical Research Foundation	Universal donor cells
WO1993004169A1 (en) *	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
EP0613495B1 (en) *	1991-11-14	2005-02-02	WEISSMANN, Charles	Transgenic non-human animals lacking prion proteins
US20020108136A1 (en) *	1997-03-21	2002-08-08	Sri	Transgenic animals produced by homologous sequence targeting
US6916654B1 (en) *	1992-06-29	2005-07-12	Oklahoma Medical Research Foundation	Universal donor cells
DE4228162C1 (de)	1992-08-25	1994-01-13	Rajewsky Klaus Dr	Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JP3741447B2 (ja) *	1992-10-23	2006-02-01	中外製薬株式会社	エンドセリン−１遺伝子の機能が欠損したマウス
AU5965294A (en) *	1993-01-08	1994-08-15	Exemplar Corporation	An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
US5610007A (en) *	1993-01-21	1997-03-11	Universite Laval	Chimeric sheets of epithelial cells
GB9308271D0 (en)	1993-04-21	1993-06-02	Univ Edinburgh	Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5650550A (en) *	1993-10-01	1997-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Mutant mice having a deficit of functional estrogen receptors
EP0773993A4 (en) *	1994-08-19	2000-07-05	Gen Hospital Corp	PORCINE CELLS TREATED BY GENETIC ENGINEERING
CA2202549C (en) *	1994-10-14	2003-08-05	Tara Seshadri	Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene
AU705616B2 (en) *	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
US6884622B1 (en)	1995-04-21	2005-04-26	Abgenix, Inc	Method for preparing a mammalian cell deficient in HPRT
JPH11510698A (ja)	1995-08-04	1999-09-21	ザジェネラルホスピタルコーポレイション	トランスジェニックブタ及びヒトｈｌａ遺伝子を有するブタ細胞
US7148054B2 (en)	1997-01-17	2006-12-12	Maxygen, Inc.	Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en)	1997-01-17	2001-12-04	Maxygen, Inc.	Evolution of whole cells and organisms by recursive sequence recombination
GB9703550D0 (en) *	1997-02-20	1997-04-09	Ppl Therapeutics Scotland Ltd	Cell mediated transgenesis
US5948653A (en)	1997-03-21	1999-09-07	Pati; Sushma	Sequence alterations using homologous recombination
DE69842225D1 (de)	1997-04-16	2011-05-26	Millennium Pharm Inc	Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
US6897066B1 (en)	1997-09-26	2005-05-24	Athersys, Inc.	Compositions and methods for non-targeted activation of endogenous genes
US6740503B1 (en)	1997-09-26	2004-05-25	Athersys, Inc.	Compositions and methods for non-targeted activation of endogenous genes
US6194633B1 (en)	1998-01-26	2001-02-27	University Of Iowa Research Foundation	Non-human animal having a functionally disrupted SLP-76 gene
ES2218994T3 (es)	1998-02-02	2004-11-16	The Johns Hopkins University School Of Medicine	Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
AU3964799A (en) *	1998-04-24	1999-11-16	University Of Nebraska Board Of Regents	Compositions and methods for the characterization and transplantation of mammalian retinal stem cells
US6733991B1 (en)	1998-05-08	2004-05-11	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses therefor
US6746852B1 (en)	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
US7531715B1 (en)	1999-01-13	2009-05-12	Ppl Therapeutics (Scotland)	Double nuclear transfer method and results thereof
CA2362098C (en) *	1999-02-05	2011-10-11	Jens-Ulrich Bulow	Human polyclonal antibodies from genetically engineered animals
US7485293B1 (en)	1999-02-18	2009-02-03	Faustman Denise L	Method for inhibiting transplant rejection
ATE375717T1 (de) *	1999-02-18	2007-11-15	Denise L Faustman	Verfahren zur inhibierung der abstossung von transplantaten
EP2301947A3 (en)	1999-02-26	2011-11-23	Millennium Pharmaceuticals, Inc.	Secreted proteins and uses thereof
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
PL354286A1 (en)	1999-08-23	2003-12-29	Dana-Farber Cancer Institutedana-Farber Cancer Institute	Pd-1, a receptor for b7-4, and uses therefor
EA013564B1 (ru)	2000-08-03	2010-06-30	Терапеутик Хьюман Поликлоналз Инк.	Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
ATE448306T1 (de)	2000-09-01	2009-11-15	Blood Res Center	Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7037652B2 (en)	2000-11-28	2006-05-02	Wyeth	Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2429722A1 (en)	2000-11-28	2002-06-06	Wyeth	Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
US7311905B2 (en)	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da)	2000-12-06	2014-11-10	Anthrogenesis Corp	Fremgangsmåde til indsamling af stamceller fra moderkagen
EP2316919B1 (en)	2001-02-14	2015-10-07	Anthrogenesis Corporation	Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en)	2001-02-14	2020-01-29	Celularity, Inc.	Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US8231878B2 (en)	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076196A1 (en)	2001-03-22	2002-10-03	Abbott Gmbh & Co. Kg	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
WO2002079499A1 (en)	2001-04-02	2002-10-10	Wyeth	Pd-1, a receptor for b7-4, and uses therefor
EP2277897A1 (en)	2001-04-16	2011-01-26	Wyeth Holdings Corporation	Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
CN1789416B (zh) *	2001-05-11	2011-11-16	协和发酵麒麟株式会社	含人抗体λ轻链基因的人类人工染色体
US7449562B2 (en) *	2001-06-29	2008-11-11	Novartis Ag	PERV screening method and use thereof
IL160307A0 (en)	2001-08-31	2004-07-25	Univ Rockefeller	Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1525323B1 (en)	2001-11-09	2015-01-21	Dana-Farber Cancer Institute, Inc.	Pgc-1beta, a novel pgc-1 homologue and uses therefor
EP2186407A1 (en)	2002-02-13	2010-05-19	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US7153685B2 (en)	2002-03-11	2006-12-26	The Board Of Trustees Of The University Of Illinois	Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040091936A1 (en) *	2002-05-24	2004-05-13	Michael West	Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
WO2003106656A2 (en)	2002-06-17	2003-12-24	Thrasos, Inc.	Single domain tdf-related compounds and analogs thereof
EP2305836A1 (en)	2002-08-20	2011-04-06	Millennium Pharmaceuticals, Inc.	Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
AU2003298775B2 (en)	2002-11-26	2008-07-17	Anthrogenesis Corporation	Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US20050048041A1 (en) *	2003-01-13	2005-03-03	Rao Mahendra S.	Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US8409861B2 (en)	2003-08-08	2013-04-02	Sangamo Biosciences, Inc.	Targeted deletion of cellular DNA sequences
US11311574B2 (en)	2003-08-08	2022-04-26	Sangamo Therapeutics, Inc.	Methods and compositions for targeted cleavage and recombination
US7888121B2 (en)	2003-08-08	2011-02-15	Sangamo Biosciences, Inc.	Methods and compositions for targeted cleavage and recombination
MXPA06003402A (es)	2003-10-07	2006-06-27	Millennium Pharm Inc	Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
US7951532B2 (en)	2003-11-12	2011-05-31	Children's Hospital Medical Center	Method of screening a midkine modulating agent
US7371539B2 (en)	2003-12-03	2008-05-13	President And Fellows Of Harvard College	Targeted polypeptide degradation
US7622108B2 (en)	2004-04-23	2009-11-24	Bioe, Inc.	Multi-lineage progenitor cells
US8410246B2 (en)	2004-06-17	2013-04-02	Thrasos, Inc.	TDF-related compounds and analogs thereof
US7288385B2 (en)	2004-06-25	2007-10-30	The Salk Institute For Biological Studies	Increasing life span by modulation of Smek
US20080184380A1 (en) *	2004-10-22	2008-07-31	Therapeutic Human Polyclonals Inc.	Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
US20060147429A1 (en) *	2004-12-30	2006-07-06	Paul Diamond	Facilitated cellular reconstitution of organs and tissues
US20060148080A1 (en) *	2004-12-30	2006-07-06	Paul Diamond	Methods for supporting and producing human cells and tissues in non-human mammal hosts
EP1874811B1 (en)	2005-04-15	2012-06-13	President and Fellows of Harvard College	Methods for modulating bone formation and mineralization by modulating KRC activity
WO2007030820A2 (en)	2005-09-09	2007-03-15	The Johns Hopkins University	Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
JP2009508596A (ja)	2005-09-19	2009-03-05	ヒストジェニックスコーポレイション	細胞支持基材及びその調製方法
DK2497780T3 (en)	2005-09-20	2015-06-01	Thrasos Innovation Inc	TDF-related compounds and analogs thereof
DK1957633T3 (en)	2005-10-13	2014-03-17	Anthrogenesis Corp	Immunomodulation USING PLACE SPEECH STEM CELLS
PT2471904T (pt)	2005-12-29	2019-02-25	Celularity Inc	População de células estaminais placentárias
AU2007235496B2 (en)	2006-03-31	2013-11-21	E. R. Squibb & Sons, L.L.C.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7875453B2 (en)	2006-06-14	2011-01-25	Bioe Llc	Differentiation of multi-lineage progenitor cells to hepatocytes
US9580515B2 (en)	2006-08-21	2017-02-28	Zensun (Shanghai) Science & Technology, Co., Ltd.	Neukinase, a downstream protein of neuregulin
PE20081216A1 (es)	2006-09-01	2008-09-04	Therapeutic Human Polyclonals Inc	Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
US20080188573A1 (en) *	2007-02-02	2008-08-07	Alcon Research, Ltd.	Use of thy1-fp transgenic mouse for the identification of ophthalmic agents
EP3763376A1 (en)	2007-02-12	2021-01-13	Celularity, Inc.	Treatment of inflammatory diseases using placental stem cells
US9200253B1 (en)	2007-08-06	2015-12-01	Anthrogenesis Corporation	Method of producing erythrocytes
NZ599825A (en)	2007-09-28	2014-10-31	Anthrogenesis Corp	Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2214708A4 (en)	2007-10-26	2011-01-12	Centocor Ortho Biotech Inc	VECTORS, HOST CELLS, METHODS OF PRODUCTION AND USES
US8101354B2 (en) *	2008-01-15	2012-01-24	University Of Kentucky Research Foundation	Method for screening for a tobiano coat color genotype
KR20240052847A (ko)	2008-08-20	2024-04-23	셀룰래리티 인코포레이티드	개선된 세포 조성물 및 그의 제조 방법
AU2009316541B2 (en)	2008-11-19	2015-08-06	Celularity Inc.	Amnion derived adherent cells
WO2010080985A1 (en)	2009-01-08	2010-07-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for induced brown fat differentiation
EP2261242A1 (en)	2009-06-10	2010-12-15	Universite Catholique De Louvain	Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
EP2483392B1 (en)	2009-09-23	2015-11-11	Davinci Biosciences LLC	Umbilical cord lining stem cells and methods and material for isolating and culturing same
WO2011088163A1 (en)	2010-01-14	2011-07-21	President And Fellows Of Harvard College	Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
CA2787685A1 (en)	2010-01-22	2011-07-28	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
DK3284818T3 (da)	2010-01-26	2022-06-20	Celularity Inc	Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
LT2556145T (lt)	2010-04-07	2016-11-10	Anthrogenesis Corporation	Angiogenezė naudojant placentos kamienines ląsteles
US8383793B2 (en)	2010-04-15	2013-02-26	St. Jude Children's Research Hospital	Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
ES2666746T3 (es)	2010-07-13	2018-05-07	Anthrogenesis Corporation	Métodos para generar linfocitos citolíticos naturales
US8969315B2 (en)	2010-12-31	2015-03-03	Anthrogenesis Corporation	Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012109238A2 (en)	2011-02-07	2012-08-16	President And Fellows Of Harvard College	Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012122512A1 (en)	2011-03-10	2012-09-13	Hco Antibody, Inc.	Recombinant production of mixtures of single chain antibodies
JP6104896B2 (ja)	2011-06-01	2017-03-29	アントフロゲネシスコーポレーション	胎盤幹細胞を使用する疼痛の治療
CA2848368C (en)	2011-09-13	2023-02-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for brown fat induction and activity using fndc5
WO2013053076A1 (en)	2011-10-10	2013-04-18	Zensun （Shanghai）Science & Technology Limited	Compositions and methods for treating heart failure
SMT201900478T1 (it)	2011-10-28	2019-09-09	Regeneron Pharma	Topi con complesso maggiore di istocompatibilita' geneticamente modificati
US9591835B2 (en)	2011-10-28	2017-03-14	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex animals
SMT202200205T1 (it)	2011-10-28	2022-07-21	Regeneron Pharma	Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
US9043996B2 (en)	2011-10-28	2015-06-02	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex animals
CN104203977A (zh)	2012-02-15	2014-12-10	诺和诺德A/S（股份有限公司）	结合肽聚糖识别蛋白1的抗体
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja)	2012-02-15	2018-10-24	ノヴォノルディスクアー／エス	骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
CN115137753A (zh)	2013-02-05	2022-10-04	细胞结构公司	来自胎盘的自然杀伤细胞
CN111484999B (zh)	2013-02-20	2024-10-25	瑞泽恩制药公司	人源化的t细胞共受体的小鼠
US20150342163A1 (en)	2013-02-22	2015-12-03	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex mice
EP3699190B9 (en)	2013-02-22	2023-10-04	Regeneron Pharmaceuticals, Inc.	Murine cell expressing humanized major histocompatibility complex
US9957506B2 (en)	2013-09-25	2018-05-01	Cornell University	Compounds for inducing anti-tumor immunity and methods thereof
AU2015206603B9 (en)	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US10077420B2 (en)	2014-12-02	2018-09-18	Histogenics Corporation	Cell and tissue culture container
EP4248744A3 (en)	2015-04-06	2023-12-27	Regeneron Pharmaceuticals, Inc.	Humanized t cell mediated immune responses in non-human animals
AU2016343978A1 (en)	2015-10-29	2018-05-17	Dana-Farber Cancer Institute, Inc.	Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
US12006550B2 (en)	2020-10-12	2024-06-11	University Of South Carolina	Targeting treatment for ADAM30 in pathological cells
CN118511853A (zh)	2021-03-31	2024-08-20	瑞泽恩制药公司	包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
WO2025058090A1 (ja) *	2023-09-13	2025-03-20	公益財団法人東京都医学総合研究所	Mhc遺伝子群欠損動物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK105582A (da) *	1982-03-11	1983-09-12	Nordisk Insulinlab	Fremgangsmaade til bestemmelse af humane hla-d(r) vaevstyper og gensonde til brug ved fremgangsmaaden

1990
- 1990-07-25 JP JP2511319A patent/JPH04501510A/ja active Pending
- 1990-07-25 WO PCT/US1990/004178 patent/WO1991001140A1/en not_active Ceased
- 1990-07-25 EP EP90911928A patent/EP0437576B1/en not_active Expired - Lifetime
- 1990-07-25 AU AU61505/90A patent/AU633958B2/en not_active Ceased
- 1990-07-25 EP EP99108460A patent/EP0950707B1/en not_active Expired - Lifetime
- 1990-07-25 AT AT99108460T patent/ATE423195T1/de not_active IP Right Cessation
- 1990-07-25 KR KR1019910700311A patent/KR100226158B1/ko not_active Expired - Fee Related
- 1990-07-25 DE DE69034263T patent/DE69034263D1/de not_active Expired - Fee Related
- 1990-07-25 DE DE69033493T patent/DE69033493D1/de not_active Expired - Lifetime
- 1990-11-09 US US07/611,020 patent/US5416260A/en not_active Expired - Lifetime
1991
- 1991-03-22 NO NO19911164A patent/NO314458B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100226158B1 (ko)	1999-10-15
EP0950707B1 (en)	2009-02-18
EP0950707A1 (en)	1999-10-20
ATE423195T1 (de)	2009-03-15
EP0437576B1 (en)	2002-07-03
JPH04501510A (ja)	1992-03-19
EP0437576A4 (en)	1992-06-10
KR920701419A (ko)	1992-08-11
AU6150590A (en)	1991-02-22
WO1991001140A1 (en)	1991-02-07
NO911164L (no)	1991-03-22
DE69034263D1 (de)	2009-04-02
AU633958B2 (en)	1993-02-11
DE69033493D1 (de)	2004-08-12
US5416260A (en)	1995-05-16
NO911164D0 (no)	1991-03-22
EP0437576A1 (en)	1991-07-24

Legal Events

Date	Code	Title	Description
2010-08-16	MK1K	Patent expired

Publication	Publication Date	Title
NO314458B1 (no)	2003-03-24	Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon
US5413923A (en)	1995-05-09	Homologous recombination for universal donor cells and chimeric mammalian hosts
EP0626012B1 (en)	2003-07-09	Homogenotization of gene-targeting events
AU2011286185B2 (en)	2014-08-14	Transgenic animals and methods of use
KR100233781B1 (ko)	1999-12-01	동종 재조합을 이용하는 단백질 제조방법
US20050149998A1 (en)	2005-07-07	Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
CN104561095A (zh)	2015-04-29	一种能够生产人神经生长因子的转基因小鼠的制备方法
KR19990007937A (ko)	1999-01-25	큰 게놈 ｄｎａ 결실 유발법
KR20190093171A (ko)	2019-08-08	CRISPR/Cas9 시스템을 통한 닭 백혈병 바이러스(Avian Leukosis Virus, ALV) 저항성 조류의 제조방법
CA2385162A1 (en)	2001-04-05	Compositions and methods for altering gene expression
JP2005504552A (ja)	2005-02-17	ターゲティングベクターの調製方法およびその使用
AU684275B2 (en)	1997-12-11	Method for defined deletions of DNA
JP2002520023A (ja)	2002-07-09	インフルエンザウイルスｍ２タンパク質の条件突然変異体
EP4219707A1 (en)	2023-08-02	Method for producing effector cell having desired specificity
KR101911515B1 (ko)	2018-10-25	단계별 면역거부반응 억제 다중유전자가 α-Ｇａｌ 유전자에 적중된 복합형질전환 세포주 및 그의 제조방법
EP4506455A1 (en)	2025-02-12	Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same
CA2037907C (en)	2006-04-04	Homologous recombination for universal donor cells and chimeric mammalian hosts
JPH10509313A (ja)	1998-09-14	トランスジェニック生物およびその使用方法